Global Retinal Drugs Market 2018-2022

  • ID: 4522354
  • Report
  • Region: Global
  • 133 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • ALLERGAN
  • Bayer
  • F Hoffmann-La Roche
  • Novartis
  • Regeneron Pharmaceuticals
  • Valeant Pharmaceuticals
  • MORE
About Retinal Drugs

Retinal drugs are the medications that are used for the treatment of retinal diseases.

The analysts forecast the global retinal drugs market to grow at a CAGR of 7.63% during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the global retinal drugs market for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, Global Retinal Drugs Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • ALLERGAN
  • Bayer
  • F. Hoffmann-La Roche
  • Novartis
  • Regeneron Pharmaceuticals
  • Valeant Pharmaceuticals
Market drivers
  • Rise in the prevalence of retinal diseases
  • For a full, detailed list, view the full report
Market challenges
  • High cost associated with retinal disease therapy
  • For a full, detailed list, view the full report
Market trends
  • Development of innovative therapies
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.

READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • ALLERGAN
  • Bayer
  • F Hoffmann-La Roche
  • Novartis
  • Regeneron Pharmaceuticals
  • Valeant Pharmaceuticals
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 05: MARKET SIZING
  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 07: MARKET SEGMENTATION BY INDICATION
  • Segmentation by indication
  • Comparison by indication
  • MD drugs
  • DED drugs
  • Others
  • Market opportunity by indication
PART 08: MARKET SEGMENTATION BY DRUG CLASS
  • Segmentation by drug class
  • Anti-VEGF agents
  • Corticosteroids
  • Others
PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE
  • Geographical segmentation
  • Regional comparison
  • Retinal drugs market in Americas
  • Retinal drugs market in EMEA
  • Retinal drugs market in APAC
  • Market opportunity
PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 13: MARKET TRENDS
  • Development of innovative therapies
  • Rise in demand for sustained-release ocular formulations
PART 14: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 15: VENDOR ANALYSIS0
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • ALLERGAN
  • Bayer
  • F. Hoffmann-La Roche
  • Novartis
  • Regeneron Pharmaceuticals
  • Valeant Pharmaceuticals
PART 16: APPENDIX

List of Exhibits
Exhibit 01: Parent market
Exhibit 02: Global ophthalmic drugs market segmentation
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global retinal drugs market – Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global retinal drugs market – Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2017
Exhibit 18: Global retinal drugs market – Market share by indication 2017-2022 (%)
Exhibit 19: Comparison by indication
Exhibit 20: Global MD drugs market – Market size and forecast 2017-2022 ($ mn)
Exhibit 21: Global MD drugs market – Year-over-year growth 2018-2022 (%)
Exhibit 22: Global DED drugs market – Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Global DED drugs market – Year-over-year growth 2018-2022 (%)
Exhibit 24: Global other retinal diseases drugs market – Market size and forecast 2017-2022 ($ mn)
Exhibit 25: Global other retinal diseases drugs market – Year-over-year growth 2018-2022 (%)
Exhibit 26: Market opportunity by indication
Exhibit 27: Global retinal drugs market share by drug class 2017 (%)
Exhibit 28: Major anti-VEGF agents approved in the market
Exhibit 29: Major corticosteroids approved in the market
Exhibit 30: Customer landscape
Exhibit 31: Global retinal drugs market – Market share by geography 2017-2022 (%)
Exhibit 32: Regional comparison
Exhibit 33: Retinal drugs market in Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 34: Retinal drugs market in Americas – Year-over-year growth 2018-2022 (%)
Exhibit 35: Top 3 countries in Americas
Exhibit 36: Retinal drugs market in EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 37: Retinal drugs market in EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 38: Top 3 countries in EMEA
Exhibit 39: Retinal drugs market in APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 40: Retinal drugs market in APAC – Year-over-year growth 2018-2022 (%)
Exhibit 41: Top 3 countries in APAC
Exhibit 42: Market opportunity
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: ALLERGAN – Overview
Exhibit 49: ALLERGAN – Business segments
Exhibit 50: ALLERGAN – Organizational developments
Exhibit 51: ALLERGAN – Geographic focus
Exhibit 52: ALLERGAN – Segment focus
Exhibit 53: ALLERGAN – Key offering
Exhibit 54: ALLERGAN – Key customers
Exhibit 55: Bayer – Overview
Exhibit 56: Bayer – Business segments
Exhibit 57: Bayer – Organizational developments
Exhibit 58: Bayer – Geographic focus
Exhibit 59: Bayer – Segment focus
Exhibit 60: Bayer – Key offerings
Exhibit 61: Bayer – Key customers
Exhibit 62: F. Hoffmann-La Roche – Overview
Exhibit 63: F. Hoffmann-La Roche – Business segments
Exhibit 64: F. Hoffmann-La Roche – Organizational developments
Exhibit 65: F. Hoffmann-La Roche – Geographic focus
Exhibit 66: F. Hoffmann-La Roche – Segment focus
Exhibit 67: F. Hoffmann-La Roche – Key offerings
Exhibit 68: F. Hoffmann-La Roche – Key customers
Exhibit 69: Novartis – Overview
Exhibit 70: Novartis – Business segments
Exhibit 71: Novartis – Organizational developments
Exhibit 72: Novartis – Geographic focus
Exhibit 73: Novartis – Segment focus
Exhibit 74: Novartis – Key offerings
Exhibit 75: Novartis – Key customers
Exhibit 76: Regeneron Pharmaceuticals – Overview
Exhibit 77: Regeneron Pharmaceuticals – Business segments
Exhibit 78: Regeneron Pharmaceuticals – Organizational developments
Exhibit 79: Regeneron Pharmaceuticals – Geographic focus
Exhibit 80: Regeneron Pharmaceuticals – Segment focus
Exhibit 81: Regeneron Pharmaceuticals – Key offerings
Exhibit 82: Regeneron Pharmaceuticals – Key customers
Exhibit 83: Valeant Pharmaceuticals – Overview
Exhibit 84: Valeant Pharmaceuticals – Business segments
Exhibit 85: Valeant Pharmaceuticals – Organizational developments
Exhibit 86: Valeant Pharmaceuticals – Geographic focus
Exhibit 87: Valeant Pharmaceuticals – Segment focus
Exhibit 88: Valeant Pharmaceuticals – Key offerings
Exhibit 89: Valeant Pharmaceuticals – Key customers
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • ALLERGAN
  • Bayer
  • F Hoffmann-La Roche
  • Novartis
  • Regeneron Pharmaceuticals
  • Valeant Pharmaceuticals
  • MORE
New Report Released: – Global Retinal Drugs Market 2018-2022

The author of the report recognizes the following companies as the key players in the global retinal drugs market: ALLERGAN, Bayer, F. Hoffmann-La Roche, Novartis, Regeneron Pharmaceuticals, and Valeant Pharmaceuticals.

Commenting on the report, an analyst from the research team said: “One trend in the market is development of innovative therapies. Researchers are focusing on the development of advanced technologies such as gene therapy, eye drops, radiation, and stem cells for the treatment of retinal diseases. Additionally, companies are also focusing on developing combination therapies for the treatment of retinal diseases.”

According to the report, one driver in the market is rise in the prevalence of retinal diseases. It has been observed that the prevalence of retinal diseases such as RVO, mCNV, diabetic retinopathy, wet AMD, and DME is high in both the developing and developed countries. One of the leading causes of visual disability in the industrialized countries is AMD.

Further, the report states that one challenge in the market is high cost associated with retinal disease therapy. The high cost of retinal drugs is limiting their widespread adoption, and in turn, inhibiting their market growth. EYLEA costs approximately $1,850 per intravitreal dose, LUCENTIS 0.5 mg costs approximately $2,000 per dose, and conbercept costs approximately $1,150 per dose.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • ALLERGAN
  • Bayer
  • F Hoffmann-La Roche
  • Novartis
  • Regeneron Pharmaceuticals
  • Valeant Pharmaceuticals
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll